Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | BCR | P11274 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688564 | 0.95 | PLK1 (0.33) | SMN1; SMN2ABL1BCR | |
| SCHEMBL1688473 | 0.83 | TYRO3 (0.31) | SMN1; SMN2ABL1BCR | |
| SCHEMBL15221438 | 0.83 | SMN1; SMN2 (0.36) | SMN1; SMN2ABL1BCR | |
| SCHEMBL15221434 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2ABL1BCR | |
| SCHEMBL3545050 | 0.77 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL24603058 | 0.76 | SMN1; SMN2 (0.31) | SMN1; SMN2ABL1BCR | |
| SCHEMBL15221435 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL1675972 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL2342271 | 0.74 | PLK2 (0.49) | SMN1; SMN2ABL1BCR | |
| SCHEMBL2868818 | 0.73 | RPS6KA3 (0.35) | SMN1; SMN2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012048129-A2 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | SMN1; SMN2 785/4885ABL1 519/4885BCR 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.